Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Nov;66 Suppl 3(Suppl 3):iii61-4.
doi: 10.1136/ard.2007.078477.

Disease activity assessment in SLE: do we have the right instruments?

Michelle Petri  1
Affiliations
Review

Disease activity assessment in SLE: do we have the right instruments?

Michelle Petri. Ann Rheum Dis. 2007 Nov.

Abstract

No new therapy has been approved for systemic lupus erythematosus (SLE) in decades. Interest in SLE by pharmaceutical and biotechnology companies has increased, leading to multiple clinical trials. Unfortunately, we have now compiled quite a long list of "failed" trials. If this was due to the fact that the studied therapy did not work in SLE, we could accept it and move on. Of concern, however, is that many of the "failed" treatments had a strong "signal" of efficacy, often in subgroup analyses that made logical sense, given what was known about the mechanism of action of the treatment. This has led, understandably, to concern that there is something wrong with SLE trial designs, particularly with SLE disease activity indices.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

References

    1. Stoll T, Stucki G, Malik J, Pyke S, Isenberg D A. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 199655756–760. - PMC - PubMed
    1. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 199926490–497. - PubMed
    1. Ward M M, Marx A S, Barry N N. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 200027664–670. - PubMed
    1. Chang E, Abrahamowicz M, Ferland D, Fortin P R. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol 200255488–497. - PubMed
    1. Ho A, Magder L, Barr S, Petri M. Decreases in anti‐double stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001442342–2349. - PubMed

MeSH terms